1.13
Lunai Bioworks Inc Aktie (LNAI) Neueste Nachrichten
Lunai Bioworks reports 35% improvement in Alzheimer’s diagnostics - Investing.com
Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline - PharmiWeb.com
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - Online Athens
Seven new option listings and two option delistings on October 1st - TipRanks
LNAI Stock Price and Chart — NASDAQ:LNAI - TradingView
Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on - PharmiWeb.com
AI Drug Discovery Pioneer Lunai Bioworks Emerges with New Identity and Streamlined 23.2M Share Structure - Stock Titan
Analyzing Climb Bio (NASDAQ:CLYM) & Lunai Bioworks (NASDAQ:RENB) - Defense World
Renovaro Biosciences Announces Reverse Stock Split - TipRanks
Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split - PharmiWeb.com
Lunai Bioworks to effect 10:1 reverse stock split - MSN
Lunai Bioworks stock plunges after announcing 10:1 reverse split By Investing.com - Investing.com UK
$1.85M NIH Grant Powers Lunai Bioworks' AI Platform to Combat Alcohol Disorder Affecting 19M Americans - Stock Titan
Top 3 Health Care Stocks You'll Regret Missing In Q3 - Sahm
Lunai Bioworks launches transformer-base platform to secure GenAI - Yahoo Finance
Lunai Bioworks (RENB) Restructures European Operations for Strat - GuruFocus
AI Drug Discovery Firm Lunai Bioworks Restructures European Business, Maintains Growth Strategy - Stock Titan
Renovaro Biosciences Faces Subsidiary Bankruptcy Impact - TipRanks
Lunai Bioworks Inc. Retains American Defense International - PharmiWeb.com
User - FinancialContent
Renovaro Inc. changes corporate name to Lunai Bioworks Inc., maintains Nasdaq symbol - Investing.com
Merger Crisis: Renovaro Threatens Legal Action After Predictive Oncology Backs Out - Stock Titan
RENBRenovaro Latest Stock News & Market Updates - Stock Titan
Enochian Biosciences Is A House Of CardsThe Pipeline Is Entirely Pre-Clinical And Management Has A Questionable History (NASDAQ:RENB) - Seeking Alpha
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):